title: Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
abstract: BACKGROUND
  We performed a study to determine whether an enrollment sequence effect noted in the PROWESS (recombinant human activated Protein C Worldwide Evaluation in Severe Sepsis) trial exists in the ADDRESS (Administration of Drotrecogin Alfa [Activated] [DrotAA] in Early Stage Severe Sepsis) trial.
  
  
  METHODS
  We evaluated prospectively defined subgroups from two large phase 3 clinical trials: ADDRESS, which included 516 sites in 34 countries, and PROWESS, which included 164 sites in 11 countries. ADDRESS consisted of patients with severe sepsis at low risk of death not indicated for treatment with DrotAA. PROWESS consisted of patients with severe sepsis with one or more organ dysfunctions. DrotAA (24 microg/kg per hour) or placebo was infused for 96 hours.
  
  
  RESULTS
  In ADDRESS and PROWESS, there was a statistically significant interaction between the DrotAA treatment effect and the sequence in which patients were enrolled. In both trials, higher mortality was associated with DrotAA use in the subgroup of patients enrolled first at study sites. Compared with placebo, PROWESS mortality was lower with DrotAA treatment for the second and subsequent patients enrolled, whereas in ADDRESS, mortality remained higher for the second patient enrolled but thereafter was lower for DrotAA-treated patients. Comparison of patients enrolled first with subsequent patients enrolled indicated that the characteristics of patients changed. Subsequently enrolled patients were treated earlier, were less likely to suffer nonserious bleeds (ADDRESS), and experienced fewer protocol violations (PROWESS).
  
  
  CONCLUSIONS
  Analyses suggest that an enrollment sequence effect was present in the ADDRESS and PROWESS trials. Analysis of this effect on outcomes suggests that it is most apparent in patients at lower risk of death. In PROWESS, this effect appeared to be associated with a reduction of the DrotAA treatment effect for the first patients enrolled at each site. In ADDRESS, this effect may have contributed to early termination of the study. The finding of an enrollment sequence effect in two separate trials suggests that trial designs, site selection and training, data collection and monitoring, and statistical analysis plans may need to be adjusted for these potentially confounding events.
  
  
  BACKGROUND
  ADDRESS trial registration number: NCT00568737. PROWESS was completed before trial registration was required.
authors.affiliation: St Luc University Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium. laterre@rean.ucl.ac.be
authors.forename: Pierre-François
authors.initials: PF
authors.lastname: Laterre
authors.forename: William L
authors.initials: WL
authors.lastname: Macias
authors.forename: Jonathan
authors.initials: J
authors.lastname: Janes
authors.forename: Mark D
authors.initials: MD
authors.lastname: Williams
authors.forename: David R
authors.initials: DR
authors.lastname: Nelson
authors.forename: Amand R J
authors.initials: AR
authors.lastname: Girbes
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dhainaut
authors.forename: Edward
authors.initials: E
authors.lastname: Abraham
mesh_terms: D000328:Adult; D000368:Aged; D017326:Clinical Trials, Phase III as Topic / Q000379:methods* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000379:methods* / Q000401:mortality; D018579:Patient Selection; D011446:Prospective Studies; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000401:mortality; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated
references.citation: N Engl J Med. 2005 Sep 29;353(13):1332-41
references.pmid: 16192478
references.citation: Pediatrics. 2003 Oct;112(4):793-9
references.pmid: 14523168
references.citation: N Engl J Med. 2001 Mar 8;344(10):699-709
references.pmid: 11236773
references.citation: Ann Intern Med. 2002 Sep 17;137(6):511-20
references.pmid: 12230353
references.citation: Arch Neurol. 2001 Dec;58(12):2009-13
references.pmid: 11735774
references.citation: CMAJ. 2001 Aug 7;165(3):311-7
references.pmid: 11517650
references.citation: Crit Care Med. 2003 Mar;31(3):834-40
references.pmid: 12626993
references.citation: Crit Care Med. 2005 Oct;33(10):2266-77
references.pmid: 16215381
references.citation: JAMA. 2000 Mar 1;283(9):1151-8
references.pmid: 10703777
references.citation: Med J Aust. 2003 Apr 7;178(7):324-8
references.pmid: 12670274
references.citation: Crit Care Med. 2004 Dec;32(12):2385-91
references.pmid: 15599140
references.citation: Stroke. 2003 Dec;34(12):2847-50
references.pmid: 14605319
references.citation: Stroke. 2003 May;34(5):1106-13
references.pmid: 12663875
references.citation: Crit Care Med. 2003 Jan;31(1):12-9
references.pmid: 12544987